REGISTER FOR THIS EVENT
From Red Flags to Referral: Integrating Imaging for Earlier ATTR-CM Diagnosis and Referral Optimisation
Thursday 25th June 2026, 13:00 - 13:45 BST | To be held virtually
For UK healthcare professionals only. This promotional virtual meeting has been funded and organised by Alnylam UK Limited.
Please note that some of the sessions will include data specific to products from Alnylam UK Limited.
AMVUTTRA® is indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients and cardiomyopathy (ATTR-CM).
AMVUTTRA® is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
AMVUTTRA® is recommended by NICE as an option for the treatment of transthyretin amyloidosis in adults with cardiomyopathy (TA1115).
AMVUTTRA® is recommended by NICE as an option for the treatment of hATTR in adults with stages 1 or 2 PN (TA868).
From Red Flags to Referral: Integrating Imaging for Earlier ATTR-CM Diagnosis and Referral Optimisation.
Thursday 25th June 2026, 13:00 - 13:45 BST
Speakers
Dr Ana Martinez-Naharro, Consultant Cardiologist, Royal Free London NHS Foundation Trust
Dr Lucia Venneri, Consultant Cardiologist, Royal Free London NHS Foundation Trust
Agenda
13:00 - 13:05 Welcome and introduction - Dr Ana Martinez-Naharro
13:05 - 13:10 Redefining first-line care in ATTR-CM: early action with AMVUTTRA - Dr Lucia Venneri
13:10 - 13:20 From suspicion to action: Where does cardiac imaging matter most? - Dr Lucia Venneri
13:20 - 13:30 Enhancing referrals: improving efficiency in practice - Dr Ana Martinez-Naharro
13:30 - 13:45 Q&A - Dr Ana Martinez-Naharro and Dr Lucia Venneri
Register for this event below:
If you have already registered, please join below:
To report an adverse event in the UK:
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard/mhra.gov.uk/ or via the Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Alnylam Pharmaceuticals at 0800 141 2569 (+44 1628 878 592) or medinfo@alnylam.com